A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers

Journal of Gastrointestinal Oncology

Volumn 4, Issue 3, 2013, Pages 319-327

  Urban, Christopher ^a   Anadkat, Milan J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cetuximab; Panitumumab; Regorafenib

Indexed keywords

ANTIBIOTIC AGENT; BENZOYL PEROXIDE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CORTICOSTEROID; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; HYDROCORTISONE; IMATINIB; ISOTRETINOIN; KERATOLYTIC AGENT; KETOCONAZOLE; MINOCYCLINE; OXALIPLATIN; PANITUMUMAB; PLACEBO; REGORAFENIB; RETINOID; SORAFENIB; STEROID; SUNITINIB; TAZAROTENE; TETRACYCLINE; TRIAMCINOLONE; VEMURAFENIB;

ACNE; ACNE VULGARIS; ACTINIC KERATOSIS; ALOPECIA; BASAL CELL CARCINOMA; BLEEDING; COLON ADENOCARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FACE RASH; FOLLICULAR RASH; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HAIR; HAIR DISCOLORATION; HAIR GROWTH; HAND FOOT SYNDROME; HUMAN; HYPERTRICHOSIS; KIDNEY CARCINOMA; KIDNEY METASTASIS; LOW DRUG DOSE; LUNG CANCER; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NAIL; NEUTROPHILIC DERMATOSIS; OVERALL SURVIVAL; PAPULOPUSTULAR ERUPTION; PARONYCHIA; PERIUNGUAL PYOGENIC GRANULOMA; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PYOGENIC GRANULOMA; REVIEW; SEBORRHEA; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; SKIN CARE; SKIN DISCOLORATION; SKIN DISEASE; SKIN FISSURE; SKIN IRRITATION; SKIN TOXICITY; SPLINTER HEMORRHAGE; SUPERINFECTION; XEROSIS;

EID: 84995804543     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2013.033     Document Type: Review

References (31)

1. Common Terminology Criteria for Adverse Events version 4.0. Available online: http://www.cancer.gov
2. Erbitux® (cetuximab) [package insert]. Branchburg, NJ and Princeton, NJ: ImClone LLC, 2010.
3. Panitumumab (Vectibix) [package insert]. Thousand Oaks, CA: Amgen Inc, 2010.
4. Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734-8.
5. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705.
6. Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 2005;23:5235-46.
7. Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008;13:1201-4.
8. Romito F, Giuliani F, Cormio C, et al. Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer 2010;18:329-34.
9. Wu PA, Balagula Y, Lacouture ME, et al. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol 2011;23:343-51.
10. Jatoi A, Dakhil SR, Sloan JA, et al. Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer 2011;19:1601-7.
11. Scope A, Agero AL, Dusza SW, et al. Randomized doubleblind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-6.
12. de Noronhae Menezes NM, Lima R, Moreira A, et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 2009;19:248-51.
13. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351-7.
14. Requena C, Llombart B, Sanmartín O. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis 2012;90:77-80.
15. Chiang H, Anadkat MJ. Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitorrelated acneiform papulopustular eruptions. JAAD 2013. [Epub ahead of print].
16. Han SS, Lee M, Park GH, et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol 2010;162:371-9.
17. Rodríguez-Murphy E, Villanueva-Herraiz S, Ortega-García MP, et al. Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer. Farm Hosp 2011;35:114-20.
18. Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009;161:515-21. 19. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19:1079-95.
19. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19:1079-95.
20. Santiago F, Gonçalo M, Reis JP, et al. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients. An Bras Dermatol 2011;86:483-90.
21. Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010;15:1002-8.
22. Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010;102:47-53.
23. Bark CM, Traboulsi RS, Honda K, et al. Disseminated Mycobacterium chelonae infection in a patient receiving an epidermal growth factor receptor inhibitor for advanced head and neck cancer. J Clin Microbiol 2012;50:194-5.
24. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55.
25. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381:295-302.
26. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
27. Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 2011;16:1508-19.
28. Nardone B, Hensley JR, Kulik L, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 2012;11:e61-5.
29. Lopez V, Pinazo I, Marti N, et al. Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect. J Eur Acad Dermatol Venereol 2009;23:959-60.
30. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-3.
31. Breaker K, Naam M, La Rosa FG, et al. Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma. Dermatol Surg 2013;39:981-7.